Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy (2020)
Sequence: CRGDKGPDC
| Experiment Id | EXP002290 |
|---|---|
| Paper | Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy |
| Peptide | iRGD |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | ~5 µg/kg siRNA equivalent |
| Rna Concentration | ~5 µg/kg |
| Mixing Ratio | SPNP formulation |
| Formulation Format | synthetic protein nanoparticle (SPNP) |
| Formulation Components | polymerized HSA + OEG + PEI + iRGD + STAT3 siRNA |
| Size Nm | 220.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | GL26 intracranial glioblastoma mouse model |
| Administration Route | intravenous (tail vein) |
| Output Type | tumor regression and survival |
| Output Value | 87.5% long-term survival; tumor eradication |
| Output Units | |
| Output Notes | STAT3 knockdown in brain tumors; immune memory upon rechallenge |
| Toxicity Notes | no systemic toxicity |
| Curation Notes |